Royalty Pharma (RPRX) to Release Quarterly Earnings on Thursday

Royalty Pharma (NASDAQ:RPRX - Get Free Report) is projected to issue its quarterly earnings data before the market opens on Thursday, February 20th. Analysts expect the company to announce earnings of $1.09 per share and revenue of $743.60 million for the quarter. Parties interested in listening to the company's conference call can do so using this link.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last issued its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.15 EPS for the quarter, topping analysts' consensus estimates of $0.99 by $0.16. Royalty Pharma had a return on equity of 24.65% and a net margin of 50.53%. On average, analysts expect Royalty Pharma to post $4 EPS for the current fiscal year and $4 EPS for the next fiscal year.

Royalty Pharma Stock Performance

Shares of RPRX traded down $0.10 during mid-day trading on Friday, reaching $32.36. The company had a trading volume of 4,822,374 shares, compared to its average volume of 4,435,420. The stock has a market capitalization of $19.07 billion, a P/E ratio of 16.77 and a beta of 0.49. The stock has a 50 day moving average of $28.43 and a two-hundred day moving average of $27.76. The company has a quick ratio of 1.54, a current ratio of 1.54 and a debt-to-equity ratio of 0.64. Royalty Pharma has a 52-week low of $24.05 and a 52-week high of $32.89.

Royalty Pharma Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, March 10th. Shareholders of record on Friday, February 21st will be given a dividend of $0.22 per share. The ex-dividend date is Friday, February 21st. This represents a $0.88 dividend on an annualized basis and a yield of 2.72%. This is an increase from Royalty Pharma's previous quarterly dividend of $0.21. Royalty Pharma's dividend payout ratio is currently 43.52%.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on RPRX shares. StockNews.com upgraded Royalty Pharma from a "hold" rating to a "buy" rating in a research report on Tuesday, November 5th. Citigroup lowered their price target on Royalty Pharma from $60.00 to $40.00 and set a "buy" rating on the stock in a research report on Friday, October 25th. Finally, TD Cowen upgraded Royalty Pharma to a "strong-buy" rating in a research report on Tuesday, December 24th. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of "Buy" and a consensus price target of $41.67.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.